TNM staging is a standardized system doctors use to describe how far a cancer has spread in your body. The three letters stand for Tumor (T), Nodes (N), and Metastasis (M), and together they create a shorthand that captures the size of the original tumor, whether it has reached nearby lymph nodes, and whether it has spread to distant organs. It is the most widely used cancer staging system in the world, maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).
What the Three Letters Mean
Each letter in a TNM classification is followed by a number or letter that describes severity. Higher numbers generally mean more advanced disease. Here’s what each component tracks:
- T (Tumor): Describes the size of the primary tumor and how deeply it has grown into surrounding tissue. T0 means no evidence of a primary tumor. T1 through T4 reflect increasing size or depth of invasion, with the exact thresholds varying by cancer type. TX means the tumor can’t be assessed. Tis refers to carcinoma in situ, meaning abnormal cells are present but haven’t invaded deeper tissue.
- N (Nodes): Indicates whether cancer has spread to nearby (regional) lymph nodes. N0 means lymph nodes are cancer-free. N1 through N3 describe increasing involvement, whether that’s more nodes affected, larger clusters, or nodes farther from the original tumor. NX means the nodes couldn’t be evaluated.
- M (Metastasis): Records whether the cancer has spread beyond the regional area to distant parts of the body. M0 means no distant spread. M1 means cancer has been found in organs or tissues far from the original site. MX means distant spread couldn’t be measured. The distinction matters: cancer in a nearby lymph node is regional spread, while cancer that has traveled to the liver, lungs, bones, or brain is distant metastasis.
How T, N, and M Combine Into Stage Groups
After each component is assigned a value, doctors combine them into an overall stage, typically expressed as a Roman numeral from 0 to IV. Stage 0 represents carcinoma in situ, where abnormal cells exist but haven’t penetrated into normal tissue. Stage I usually means a small tumor with no lymph node involvement and no distant spread. Stages II and III reflect larger tumors, deeper invasion, or regional lymph node involvement in various combinations. Stage IV means distant metastasis is present, regardless of the tumor’s size or lymph node status.
The exact combinations that produce each stage differ by cancer type. A T2 N0 M0 breast cancer and a T2 N0 M0 lung cancer may fall into different overall stages because the biology and prognosis of those cancers are different. This is why staging manuals run hundreds of pages, with separate tables for each organ.
Clinical Staging vs. Pathological Staging
You may see the letters “c” or “p” in front of a TNM classification, and they mean very different things. Clinical staging (cTNM) is based on information gathered before surgery: physical exams, imaging scans like CT or MRI, biopsies, and blood work. It represents the best estimate of how far the cancer has spread using non-surgical methods.
Pathological staging (pTNM) comes after surgery, when a pathologist examines the removed tumor and lymph nodes under a microscope. Because it’s based on direct examination of tissue, pathological staging is generally more accurate. It can reveal cancer in lymph nodes that looked normal on imaging, or show that a tumor invaded deeper than scans suggested. When both are available, pathological staging typically carries more weight in treatment decisions.
Other prefixes exist for specific situations. A “y” prefix (ypTNM) means staging was done after the patient received chemotherapy or radiation before surgery. An “r” prefix indicates staging of a cancer that has recurred after a period of being disease-free.
Why Staging Matters for Treatment
TNM staging directly shapes what treatment options are recommended. Early-stage cancers (Stage I and some Stage II) can often be treated with surgery alone or surgery plus a short course of radiation. More advanced regional disease (Stage II or III) frequently calls for a combination of surgery, radiation, and systemic treatments like chemotherapy or immunotherapy. Stage IV cancers, where distant metastasis is present, are typically treated with systemic therapies designed to reach cancer cells throughout the body, though surgery or radiation may still be used in specific situations to manage symptoms or target isolated spots of spread.
Staging also provides a common language. When oncologists, surgeons, radiologists, and pathologists discuss a case, TNM staging ensures everyone is working from the same description of the disease. It’s equally important for research, because clinical trials use staging to define which patients are eligible and to compare outcomes across treatment groups.
The Current Staging System
The AJCC has shifted from publishing a single staging manual to releasing a versioned staging system that updates cancer types on a rolling basis rather than all at once. Most cancers are still staged using the criteria from the 8th Edition Cancer Staging Manual, which has been in effect since 2018. The newer Version 9 is rolling out by disease site: lung, thymus, diffuse pleural mesothelioma, and nasopharynx transitioned to Version 9 criteria in 2025, with salivary gland and HPV-associated oropharyngeal cancers following on January 1, 2026. All other disease sites remain under 8th Edition rules until their Version 9 updates are released.
This rolling approach means the staging criteria your oncologist uses depend on what type of cancer is being evaluated and when. If you’re looking at a pathology report or staging document, the edition or version number should be noted so the classification can be interpreted correctly.
Reading Your Own Staging Report
If you’ve received a TNM classification on a pathology or radiology report, here’s a practical way to interpret it. Look at each component separately. The T value tells you about the original tumor’s size and local extent. The N value tells you whether nearby lymph nodes are involved and roughly how many. The M value tells you whether the cancer has traveled to distant sites. Then look at the overall stage group (0 through IV), which your oncology team uses as the primary framework for recommending next steps.
Keep in mind that the same overall stage can look very different between two people. Two patients both classified as Stage III may have different T, N, and M combinations, different tumor biology, and different treatment paths. For many cancers, additional factors beyond TNM now influence the final prognostic stage, including tumor grade (how abnormal the cells look), specific molecular markers, and biomarker test results. These factors can shift a cancer’s overall stage up or down compared to what the T, N, and M values alone would suggest.